Besides the NKT and MAIT cells, NK-like T cell family encompasses a heterogeneous population of cells most of which remain largely unknown. By combining scRNA-seq, fate mapping and transgenic mouse models, we defined a novel population of NK-like T helper cells (referred to as NLCs) that are nonrestricted to CD1d, MR1 and microbiome-derived antigens, lack γδTCR expression, and reside predominantly within the vasculature in the liver. Although, NLCs are not restricted to the known classical and non-classical MHC molecules, they require the thymus for their development. Compared to other T cells in the liver, NLCs depict a unique transcriptional signature, moderate cytotoxic capacity and express molecules that are so far have been described only in NK cells. Upon viral infection or TCR stimulation, NLCs release IL-2, IFNg, CCL3, CCL5 and XCL1 indicating T helper like and innate lymphocytes functions. Importantly, intra-tumoral injection or systemic transfer of NLCs from healthy mice reinvigorated dysfunctional antigen-specific CD8 T cells and promoted cancer immune control and viral clearance in chronic LCMV infection respectively. Collectively, our study identifies a previously unknown T helper cell subset that may be exploited to develop novel immune therapies.